Published in Hum Immunol on January 12, 2009
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology (2012) 1.56
Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans. Transplantation (2013) 0.98
Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Transplantation (2011) 0.93
Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. Hum Immunol (2011) 0.89
Human leukocyte antigen-G expression on dendritic cells induced by transforming growth factor-beta1 and CD4+ T cells proliferation. Iran Biomed J (2011) 0.79
Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses. PLoS One (2016) 0.77
JC virus T-Antigen DNA in gastrointestinal mucosa of immunosuppressed patients: a prospective, controlled study. Dig Dis Sci (2009) 0.75
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 6.49
Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A (2008) 3.40
Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol (2001) 2.75
Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest (2008) 2.73
Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol (2007) 2.61
Weaning of immunosuppression in living donor liver transplant recipients. Transplantation (2001) 2.18
Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood (2005) 2.17
Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes (2006) 1.65
Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl (2006) 1.57
Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57
CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant (2008) 1.55
Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant (2004) 1.49
The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol (2000) 1.45
Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant (2004) 1.40
Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol (2006) 1.40
Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology (2004) 1.36
IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol (2008) 1.34
An appraisal of tolerance in liver transplantation. Am J Transplant (2006) 1.32
CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol (2006) 1.26
Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant (2003) 1.21
Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology (1998) 1.21
Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation (2006) 1.16
Rapamycin impairs antigen uptake of human dendritic cells. Transplantation (2003) 1.13
Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells. J Immunol (2006) 1.09
Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant (2005) 1.09
Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol (2000) 1.07
Influence of immunosuppressive drugs on dendritic cells. Transpl Immunol (2003) 0.96
Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Investig Med (2001) 0.95
Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant (2008) 0.92
Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up. Transplant Proc (1997) 0.92
Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. Transpl Immunol (2007) 0.89
Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc (2005) 0.82
Tolerance and latent cellular rejection in long-term liver transplant recipients. Hepatology (1998) 0.81
Complete withdrawal of immunosuppression in living donor liver transplantation. Transplant Proc (2002) 0.79
Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med (2013) 7.40
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 3.57
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology (2008) 3.52
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol (2009) 3.43
Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med (2012) 3.27
Pediatric nurses' beliefs and pain management practices: an intervention pilot. West J Nurs Res (2010) 2.73
Measuring the significance of field validation in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology: how good are the experts? Arch Pathol Lab Med (2005) 2.69
Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg (2007) 2.67
Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. Eur Heart J (2012) 2.59
Physical activity participation among persons with disabilities: barriers and facilitators. Am J Prev Med (2004) 2.48
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35
Autologous options for postmastectomy breast reconstruction: a comparison of outcomes based on the American College of Surgeons National Surgical Quality Improvement Program. J Am Coll Surg (2012) 2.20
State of the art in trueness and interlaboratory harmonization for 10 analytes in general clinical chemistry. Arch Pathol Lab Med (2008) 2.15
Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology (2014) 2.14
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet (2012) 2.13
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation (2003) 1.98
A comprehensive risk assessment of mortality following donation after cardiac death liver transplant - an analysis of the national registry. J Hepatol (2011) 1.94
Intrahepatic biliary cystadenoma: role of cyst fluid analysis and surgical management in the laparoscopic era. Surgery (2004) 1.89
Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA (2010) 1.84
Applying multimedia design principles enhances learning in medical education. Med Educ (2011) 1.80
Creatinine measurement: state of the art in accuracy and interlaboratory harmonization. Arch Pathol Lab Med (2005) 1.77
Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci U S A (2012) 1.66
Mucosal vascular alterations in isolated small-bowel allografts: relationship to humoral sensitization. Am J Transplant (2003) 1.64
Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J Neurosci (2002) 1.58
Laparoscopic liver surgery: Shifting the management of liver tumors. Hepatology (2006) 1.58
Barriers associated with exercise and community access for individuals with stroke. J Rehabil Res Dev (2008) 1.57
Distribution of the tight junction proteins ZO-1, occludin, and claudin-4, -8, and -12 in bladder epithelium. Am J Physiol Renal Physiol (2004) 1.57
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology (2012) 1.56
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl (2006) 1.56
Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl (2010) 1.56
MRI predictors of cognitive change in a diverse and carefully characterized elderly population. Neurobiol Aging (2010) 1.56
Stretch-regulated exocytosis/endocytosis in bladder umbrella cells. Mol Biol Cell (2002) 1.56
Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology (2010) 1.55
Resident involvement and plastic surgery outcomes: an analysis of 10,356 patients from the American College of Surgeons National Surgical Quality Improvement Program database. Plast Reconstr Surg (2013) 1.54
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations. Am J Transplant (2011) 1.51
Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. Liver Transpl (2014) 1.50
Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation (2013) 1.50
Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J Hepatol (2009) 1.50
Demographic, psychosocial, and behavioral factors associated with survival after heart transplantation. Ann Thorac Surg (2013) 1.48
Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res (2010) 1.46
Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology (2004) 1.45
Relevance of the c-statistic when evaluating risk-adjustment models in surgery. J Am Coll Surg (2012) 1.45
Heterogeneity of cognitive trajectories in diverse older persons. Psychol Aging (2010) 1.44
Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology (2009) 1.44
Regulation of alloimmune responses (GvH reactions) in vitro by autologous donor bone marrow cell preparation used in clinical organ transplantation. Transplantation (2002) 1.42
Phenytoin overview--metabolite interference in some immunoassays could be clinically important: results of a College of American Pathologists study. Arch Pathol Lab Med (2003) 1.41
The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery (2009) 1.39
A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation (2002) 1.32
Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant (2005) 1.32
Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation (2003) 1.28
Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol (2007) 1.26
A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation (2005) 1.25
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol (2010) 1.25
Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology (2011) 1.25
Inoculation against falls: rapid adaptation by young and older adults to slips during daily activities. Arch Phys Med Rehabil (2010) 1.24
Recruitment of African American women to a walking program: eligibility, ineligibility, and attrition during screening. Res Nurs Health (2006) 1.21
Laparoscopic-assisted vs. open colectomy for cancer: comparison of short-term outcomes from 121 hospitals. J Gastrointest Surg (2008) 1.18
Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol (2009) 1.18
Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer (2010) 1.15
Neighborhood environment and adherence to a walking intervention in African American women. Health Educ Behav (2008) 1.14
Accessibility of health clubs for people with mobility disabilities and visual impairments. Am J Public Health (2005) 1.13
Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model. Transplantation (2007) 1.13
Allosensitization of islet allograft recipients. Transplantation (2007) 1.13
Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. Liver Transpl (2003) 1.12
Obesity prevalence among a group of Chicago residents with disabilities. Arch Phys Med Rehabil (2005) 1.11
Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation (2002) 1.11
Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis. Ann Surg (2011) 1.11
Outcomes of a home-based walking program for African-American women. Am J Health Promot (2008) 1.09
Comparative effectiveness of donation after cardiac death versus donation after brain death liver transplantation: Recognizing who can benefit. Liver Transpl (2012) 1.08
Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol (2013) 1.08
Relation of plasma homocysteine to plasma amyloid beta levels. Neurochem Res (2006) 1.06
Women's health issues with fibromyalgia syndrome. J Womens Health (Larchmt) (2006) 1.06
The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation. Transplantation (2009) 1.06
The economic impact of MELD on liver transplant centers. Am J Transplant (2005) 1.05
Analytic bias of thyroid function tests: analysis of a College of American Pathologists fresh frozen serum pool by 3900 clinical laboratories. Arch Pathol Lab Med (2005) 1.04
Lack of specificity of cyclosporine immunoassays. Results of a College of American Pathologists Study. Arch Pathol Lab Med (2003) 1.04
Menopausal status, moderate-intensity walking, and symptoms in midlife women. Res Theory Nurs Pract (2005) 1.03
Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology (2012) 1.01
Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation (2007) 1.01
The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant (2005) 1.01
Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation (2005) 1.00
Prospective measurements of intra-abdominal volume and pulmonary function after repair of massive ventral hernias with the components separation technique. Ann Surg (2010) 0.99
The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation (2004) 0.99
Aerobic exercise training in stroke survivors. Top Stroke Rehabil (2005) 0.99
Teaching for understanding in medical classrooms using multimedia design principles. Med Educ (2013) 0.99